 |
tumor-inflitrating lymphocytes; LN-144 |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant melanoma Stages IIb to IV |
| USA Market Approval | USA |
| USA Designation Date | 2015-06-09 00:00:00 |
| Sponsor | Iovance Biotherapeutics, Inc.;999 Skyway Road, Suite 150;San Carlos, California, 94070 |
